Christian Glennie
Christian Glennie joined the healthcare team at Edison Investment Research in January 2012 and has 11 years' experience covering the global biotech/pharmaceutical sector as an analyst and a journalist. He came to Edison having held senior analyst and editorial roles at EvaluatePharma and EP Vantage. Christian Glennie also has prior experience as a marketing analyst at Zeneca Agrochemicals.
Recent Quotes
"ATHX's MultiStem in ischemic stroke showed a favorable safety profile."
—
Christian Glennie, Edison Investment Research
(5/5/15)
more >
"Positive Phase 2 data in ischemic stroke could significantly rerate ATHX stock."
—
Christian Glennie, Edison Investment Research
(3/5/15)
more >
"We estimate ATHX's MultiStem to hit peak sales of $3B across the US, EU and Japan."
—
Christian Glennie, Edison Investment Research
(1/12/15)
more >
"ATHX is well positioned in terms of its stage of development and the profile of its MAPCs."
—
Christian Glennie, Edison Investment Research
(11/24/14)
more >
"Positive Phase 2 data in ischemic stroke could rerate ATHX's stock."
—
Christian Glennie, Edison Investment Research
(9/24/14)
more >
"ATHX's Phase 2, ischemic stroke study results are expected in Q4/14."
—
Christian Glennie, Edison Investment Research
(6/30/14)
more >
"Potential FDA clearance for VRS' Aura is a key near-term catalyst."
—
Christian Glennie, Edison Investment Research
(6/30/14)
more >
"A key, near-term catalyst for VRS is 501(k) FDA clearance for Aura."
—
Christian Glennie, Edison Investment Research
(6/2/14)
more >
